Activation of transforming growth factor-β1 and early atherosclerosis in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 8, Issue 3, 2006, Pages

  Jackson, Michelle ^a   Ahmad, Yasmeen ^b   Bruce, Ian N ^b   Coupes, Beatrice ^a   Brenchley, Paul E C ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ATHEROSCLEROSIS; BLOOD; CAUCASIAN; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE; MALE; PATHOLOGY; REFERENCE VALUE; SYSTEMIC LUPUS ERYTHEMATOSUS; TUNICA MEDIA; UNITED KINGDOM;

APOPTOSIS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; ENGLAND; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; REFERENCE VALUES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUNICA MEDIA;

EID: 34447522347     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1951     Document Type: Article

References (31)

1. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta Annu Rev Immunol 1998, 16:137-161.
2. 1 null mouse phenotype. Proc Natl Acad Sci USA 1993, 90:9944-9948.
3. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjogren's syndromelike lymphoproliferation in TGF-beta knockout mice. J Immunol 1995, 155:3205-3212.
4. Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA: Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998, 160:2539-2545.
5. Ohtsuka K, Gray JD, Quismorio FP Jr, Lee W, Horwitz DA: Cytokine-mediated down-regulation of B cell activity in SLE: Effects of interleukin-2 and transforming growth factor-beta. Lupus 1999, 8:95-102.
6. Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26:257-278.
7. Grainger DJ: Transforming growth factor beta anS atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004, 24:399-404.
8. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994, 370:460-462.
9. Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP: Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 2000, 113:2355-2361.
10. Mallat Z, Tedgui A: The role of transforming growth factor beta in atherosclerosis: Novel insights and future perspectives. Curr Opin Lipidol 2002, 13:523-529.
11. Hahn BH: Systemic lupus erythematosus and accelerated atherosclerosis N Engl J Med 2003, 349:2379-2380.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
13. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, et al.: The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:809-813.
14. Mackness MI, Durrington PN: Lipoprotein analysis for clinical studies In Lipoprotein Analysis: A Practical Approach Edited by: Converse CA, Skinner ER. Oxford: IRL Press; 1992:1-42.
15. Coupes BM, Newstead CG, Short CD, Brenchley PE: Transforming growth factor beta 1 in renal allograft recipients. Transplantation 1994, 57:1727-1731.
16. Coupes BM, Williams S, Roberts IS, Short CD, Brenchley PE: Plasma transforming growth factor beta(1) and platelet activation: Implications for studies in transplant recipients. Nephrol Dial Transplant 2001, 16:361-367.
17. Sidhu PS, Desai SR: A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Br J Radiol 1997, 70:85-89.
18. Kropf J, Schurek JO, Wollner A, Gressner AM: Immunological measurement of transforming growth factor-beta I (TGF-beta 1) in blood; assay development and comparison. Clinical Chemistry 1997, 43:1965-1974.
19. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC: Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nature Medicine 1995, 1:932-937.
20. Lawrence DA: Latent-TGF-beta: an overview. Mol Cell Biochem 2001, 219:163-170.
21. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994, 152:3685-3692.
22. Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997, 40:306-317.
23. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M: High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998, 7:113-118.
24. Gergely P Jr, Niland B, Gonchoroff N, Pullmann R Jr, Phillips PE, Perl A: Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol 2002, 169:1092-1101.
25. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
26. Bruce IN: Cardiovascular disease in Supus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005, 19:823-838.
27. Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC: Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res 1997, 38:2344-2352.
28. Sakamoto YI, Miyazaki A, Tamagawa H, Wang GP, Horiuchi S: Specific interaction of oxidized low-density lipoprotein with thrombospondin-1 inhibits transforming growth factor-beta from its activation. Atherosclerosis 2005, 183:85-93.
29. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C: Cardiovascular risk in systemic lupus erythematosus: Evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford) 2003, 42 758-762.
30. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
31. Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ: Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996, 271 31367-31371.